Topiramate
Migraine, Caloric Restriction, High cholesterol + 16 more
Treatment
20 Active Studies for Topiramate
Treatment for
Migraine
What is Topiramate
Topiramate
The Generic name of this drug
Treatment Summary
Topiramate is a medication used to control seizures and prevent migraine headaches. It was first approved by the FDA in 1996 and later approved for migraine prevention in adults in 2004. Topiramate is also used in combination with phentermine to help adults manage their weight. It contains a monosaccharide chemical structure with sulfamate and 40% of its mass is oxygen. Topiramate was originally developed as an antidiabetic drug, but was found to be an effective antiepileptic drug by chance.
Topamax
is the brand name
Topiramate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Topamax
Topiramate
1997
526
Effectiveness
How Topiramate Affects Patients
Topiramate helps to stop seizures and migraine symptoms by calming down the nerve pathways in the brain. However, it can also cause health problems like acid in the blood, changes in mood, suicidal thoughts, and kidney stones. Taking topiramate together with another drug called valproic acid may also cause a low body temperature.
How Topiramate works in the body
Seizures are caused by an uncontrolled electrical discharge in the brain. Topiramate helps to control seizures and migraines by increasing the activity of GABA-A receptors, which are usually inhibitory, and decreasing glutamate activity, which is usually stimulating. It also blocks voltage-dependent sodium channels, preventing seizures from occurring. Lastly, it has been seen to inhibit carbonic anhydrase isozymes, though the impact of this is not yet known.
When to interrupt dosage
The proposed dosage of Topiramate is contingent upon the diagnosed state, for example Seizures, Weight Reduction and Tonic - clonic seizures. The measure can be found in the accompanying table, based on the mode of administration (e.g. Tablet, coated or Tablet).
Condition
Dosage
Administration
Alcoholism
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Obesity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Exercise
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Lennox Gastaut Syndrome
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Migraine
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Caloric Restriction
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
High cholesterol
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Obesity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
at least one weight-related comorbid condition
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Migraine Disorders
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Obesity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Seizures
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Type 2 Diabetes
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Hypertensive disease
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Epilepsy
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Weight Loss
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
increase in physical activity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Mood Disorders
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Chronic Weight Management therapy
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, coated, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule - Oral, Capsule, Solution, Solution - Oral
Warnings
Topiramate Contraindications
Condition
Risk Level
Notes
Acidosis
Do Not Combine
There are 20 known major drug interactions with Topiramate.
Common Topiramate Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Topiramate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Topiramate.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be increased when combined with Topiramate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Topiramate.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Topiramate.
Topiramate Toxicity & Overdose Risk
The lowest toxic dose of topiramate in rats is greater than 1500mg/kg. In a study of 4 women taking topiramate, symptoms of overdose ranged from mild to severe, but no deaths were reported. Symptoms of overdose may include low blood pressure, extreme acidity in the body, coma, abdominal pain, vision problems, seizures, drowsiness, difficulty speaking or thinking, confusion or agitation, dizziness, and depression. If the overdose was recent, the stomach contents can be emptied using vomiting or a stomach pump. Treatment may also include activated charcoal and dialysis.
Topiramate Novel Uses: Which Conditions Have a Clinical Trial Featuring Topiramate?
313 clinical trials are currently underway to assess the potential of Topiramate to treat Type 2 Diabetes, Migraine and Exercise-related conditions.
Condition
Clinical Trials
Trial Phases
Exercise
57 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Weight Loss
0 Actively Recruiting
Mood Disorders
0 Actively Recruiting
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Obesity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Migraine Disorders
1 Actively Recruiting
Phase 3
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Seizures
5 Actively Recruiting
Phase 3, Phase 2, Phase 1
High cholesterol
0 Actively Recruiting
Obesity
0 Actively Recruiting
at least one weight-related comorbid condition
0 Actively Recruiting
Lennox Gastaut Syndrome
2 Actively Recruiting
Phase 1, Phase 2, Phase 4
Obesity
0 Actively Recruiting
Caloric Restriction
0 Actively Recruiting
Epilepsy
0 Actively Recruiting
Alcoholism
7 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Type 2 Diabetes
162 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
increase in physical activity
0 Actively Recruiting
Topiramate Reviews: What are patients saying about Topiramate?
4.3
Patient Review
3/20/2022
Topiramate for Migraine Prevention
4
Patient Review
2/21/2022
Topiramate for Migraine Prevention
3.7
Patient Review
3/25/2022
Topiramate for Migraine Prevention
2
Patient Review
3/6/2022
Topiramate for Migraine Prevention
1.7
Patient Review
3/31/2022
Topiramate for Migraine Prevention
1
Patient Review
4/29/2022
Topiramate for Tonic-Clonic Epilepsy
1
Patient Review
5/2/2022
Topiramate for Migraine Prevention
1
Patient Review
5/9/2022
Topiramate for Migraine Prevention
Patient Q&A Section about topiramate
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the serious side effects of topiramate?
"If you experience any of the following side effects, it could be a sign of a more serious condition and you should seek medical attention immediately: pain in your back, belly or side; a burning sensation when you pee; cloudy or smelly pee; feeling sleepy; losing your appetite; or having an irregular heartbeat."
Answered by AI
What is the most common side effect of topiramate?
"You may experience fatigue, drowsiness, dizziness, loss of coordination, tingling in your extremities, decreased appetite, bad taste in your mouth, diarrhea, and weight loss."
Answered by AI
What does Topamax do to your body?
"Topiramate is a type of medication used to treat seizures. It works by decreasing the abnormal excitement in the brain."
Answered by AI